A detailed history of First Trust Advisors LP transactions in Arvinas, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 139,313 shares of ARVN stock, worth $3.71 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
139,313
Holding current value
$3.71 Million
% of portfolio
0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$36.38 - $52.31 $5.07 Million - $7.29 Million
139,313 New
139,313 $5.75 Million
Q4 2022

Feb 09, 2023

BUY
$32.47 - $57.24 $768,175 - $1.35 Million
23,658 New
23,658 $809,000
Q2 2022

Aug 12, 2022

BUY
$36.01 - $74.24 $289,268 - $596,369
8,033 New
8,033 $338,000
Q1 2022

May 13, 2022

SELL
$60.27 - $81.57 $2.22 Million - $3.01 Million
-36,893 Closed
0 $0
Q4 2021

Feb 08, 2022

BUY
$65.85 - $96.21 $1.08 Million - $1.58 Million
16,473 Added 80.67%
36,893 $3.03 Million
Q3 2021

Nov 15, 2021

BUY
$73.2 - $107.87 $1.49 Million - $2.2 Million
20,420 New
20,420 $1.68 Million
Q2 2021

Aug 16, 2021

SELL
$60.45 - $84.26 $2.61 Million - $3.63 Million
-43,109 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$58.19 - $91.37 $1.85 Million - $2.91 Million
31,839 Added 282.51%
43,109 $2.85 Million
Q4 2020

Feb 02, 2021

SELL
$20.19 - $84.93 $323,524 - $1.36 Million
-16,024 Reduced 58.71%
11,270 $957,000
Q3 2020

Nov 05, 2020

SELL
$22.99 - $36.34 $395,979 - $625,920
-17,224 Reduced 38.69%
27,294 $644,000
Q2 2020

Jul 22, 2020

BUY
$29.88 - $56.74 $437,174 - $830,162
14,631 Added 48.95%
44,518 $1.49 Million
Q1 2020

May 06, 2020

BUY
$33.0 - $54.5 $986,271 - $1.63 Million
29,887 New
29,887 $1.2 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.42B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.